Efficacy and safety of BEBT-209, a primary CDK4 inhibitor, in combination with gemcitabine and carboplatin for metastatic triple-negative breast cancer.

BEBT-209 - BeBetter Med

Trodelvy (sacituzumab govitecan-hziy) - Gilead

gemcitabine - Generic mfg.

carboplatin - Generic mfg.

Quchang Ouyang; Yongkui Lu; Huihui Li; Jiuwei Cui; Yunjiang Liu; Tao Wu; Tao Sun; Jun Xiao; Changgeng Qian; Qiang Liu

Apr 23, 2025